Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PDSB
#3621
PDS Biotechnology Corporation Common Stock
0.6
8
-1.45%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
-1.45%
Aylık değişim
-32.00%
6 aylık değişim
-47.29%
Yıllık değişim
-52.45%
Önceki kapanış
0.6
9
Open
0.6
8
Bid
Ask
Low
0.6
8
High
0.6
8
Hacim
6
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
PDSB
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Cash from operating activities
-8 M
-8.23 M
-9.03 M
-9.1 M
-5.92 M
-32.28 M
Cash from investing activities
—
—
—
—
—
—
Cash from financing activities
17.22 K
172.78 K
7.32 M
995.94 K
241.2 K
8.73 M
Free cash flow
-8 M
-8.23 M
-9.03 M
-9.1 M
-5.92 M
-32.28 M
Haberler
PDS Biotech amends Phase 3 trial to add accelerated approval path
PDS Biotech reports 9.6-month progression-free survival in prostate cancer study
PDS Biotech secures patent for cancer immunotherapy PDS0101
PDS Biotech stock soars after FDA meeting provides accelerated approval path
PDS Biotech submits amended protocol for phase 3 cancer trial
PDS Biotech secures new patent for cancer immunotherapy in Japan
PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why
PDS Biotech secures FDA meeting to discuss accelerated approval pathway
PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript
PDS Biotech raises $5.3 million in registered direct offering
PDS Biotechnology stock falls after $5.3 million registered direct offering
PDS Biotech reports positive data on cancer immunotherapy mechanisms